Systematic review and meta-analysis of Saccharomyces boulardii in adult patients

Table 6 Summary of recommendations for clinical use of S. boulardii in adults

Use for disease	Dose (mg/d)	Duration	Adjunct to	Strength of evidence1
Prevention of antibiotic associated diarrhea	500-1000	During antibiotics with additional 3 d to 2 wk after	Nothing	++++
Prevention of Traveler’s diarrhea	250-1000	Duration of trip (3 wk)	Nothing	+++
Enteral nutrition-related diarrhea	2000	8-28 d	Nothing	++
H. pylori symptoms	1000	2 wk	Standard triple therapy	++
Treatment of Clostridium difficile infections	1000	4 wk	Vancomycin or metronidazole	+
Acute adult diarrhea	500-750	8-10 d	Nothing	+
Inflammatory bowel disease	750-1000	7 wk to 6 mo	Mesalamine	+
Irritable bowel syndrome	500	4 wk	Nothing	+
Giardiasis	500	4 wk	Metronidazole	+
HIV-related diarrhea	3000	7 d	Nothing	+

¹Strength of evidence, + (weak, needs more randomized controlled trials) to ++++ (strong, efficacy and safety are evidence based from numerous large randomized controlled trials).